Further analysis of our breast cancer PDTXs revealed enrichment of Bev resistance genes in human, but not mouse, genes that correlate with human FOXC2-targets (Fig 6E), suggesting that the Bevacizumab resistance gene signature is of tumor origin. Here, FOXC2 is linked to neoplasm.